Hombrechtikon ZH – PreComb has raised new funding of 2.2 million Swiss francs in a seed financing round. The biotech has developed a technology platform for personalized medicine for cancer patients. This will make it possible to directly test the drug response of individual cancer patients.

PreComp raises CHF 2.2 mio

PreComb Therapeutics AG from the canton of Zurich has secured investment of 2.2 million francs in a seed financing round. The round was led by the Austrian subsidiary of the Hong Kong investment company Kinled and the Zurich-based FiveT Group.

PreComb has developed 3D technology for the functional patient-specific drug testing of cancer therapies. This point-of-care technology enables clinical institutions to test a large number of therapies directly. While a press release explains that personalized therapies have become a prime focus, current patient-specific molecular and histopathological information is not sufficient to enable personalized medicine for most patients.

“In recent years, we have seen a change of dogma in the treatment of cancer,” said Jens M. Kelm, co-founder and CEO of PreComb. “However, to achieve the full benefit of personalized medicine decisions for most patients, we need fully translatable testing platforms that directly assess individual drug sensitivity and resistance and can be implemented on-site in the clinic.” The PreComb test platform enables clinical institutions to test a large number of therapies directly on 3D microtumors generated from patient tumors.

“We look forward to supporting PreComb to help cancer patients receive the most promising therapies and take advantage of the immense opportunities ahead,” noted Patrick Aisher, managing partner at Kinled Austria. He has joined the Board of Directors of PreComb.

Contact us

Can we put you in touch with a peer company or research institute? Do you need any information regarding your strategic expansion to Switzerland's technology and business center? Give us a call or drop us a line. 

+41 44 254 59 59